tbuckley/cabot-search huggingface dataset:
Safeguarding in sport
Authors: Michael Turner
Journal: British Journal of Sports Medicine (2017)

When I was a baby doctor who only shaved once a week, I used to give a talk entitled Child Protection. The audience invariably thought that this was going to be a gentle guide to helmets and mouthguards and were distinctly uncomfortable when my starting sentence was 'As you know, youth sport is a magnet for paedophiles'. The fact that this was in 1994, in the wake of the Hickson swimming scandal, shows just how long it has taken some sports to wake up to the problem. Safeguarding athletes from exploitation and abuse should be the no. 1 priority for everyone involved in sport.

However, no. 2 on our priority list should be safeguarding athletes from ignorance, a problem that has frustrated sports physicians since the dawn of time.

From the moment that an athlete ruptures an ACL, their knee is doomed. You can speed up the rate of deterioration by encouraging the athlete to return to the activity that caused the injury in …
Omalizumab Is Associated with Reduced Acute Severity of Rhinovirus-triggered Asthma Exacerbation
Authors: David B. Kantor, Molly C. McDonald, Nicole Stenquist, Blake J. Schultz, Craig D. Smallwood, Kyle A. Nelson, Wanda Phipatanakul, Joel N. Hirschhorn
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

populations, these results should be interpreted in light of their limitations.First, the study population is limited to U.S. ICUs, and the coding algorithms may not generalize internationally.Second, the study was performed in an era of ICD-9 reporting and could not evaluate the performance of ICD-10 codes.However, all claims-based ICU studies are still using ICD-9 codes.Although we would not expect the ICD-10 crosswalk to yield different results, future studies are needed to address this issue.On the basis of these findings, we recommend that researchers can use ICD-9 procedure codes for mechanical ventilation alone to identify populations of mechanically ventilated patients in administrative data, with the understanding that the population captured will not represent the entire population of mechanically ventilated patients.These data suggest that researchers can be confident that identified patients will have truly been ventilated and will help characterize the patients who may have been missed by ICD-9 procedure codes.
Potent Inhibition of EEC Colony Formation in JAK2V617F PV and ET by Low Doses of ITF2357, a New Histone Deacetylase Inhibitor.
Authors: Vittoria Guerini, Orietta Spinelli, Anna Salvi, Guido Finazzi, Tiziano Barbui, Martino Introna, Josee Golay, Alessandro Rambaldi
Journal: Blood (2006)
Myelodysplastic Syndromes (MDS) with Erythroid Hyperplasia: Enumerating Blasts from Non-Erythroid Cell Compartment Improves the Risk Stratification of MDS with Excess of Blasts
Authors: Leonor Arenillas, Xavier Calvo, Mar Tormo, David Valcárcel, Elisa Luño, Esther Alonso, María Consuelo Cañizo, Fernando Ramos, Carmen Pedro, Beatriz Arrizabalaga, Alicia Bailén, José María Raya, María Teresa Ardanaz, Guillermo Sanz, Lourdes Florensa
Journal: Blood (2015)
Increased Expression Level of Noxa in Peripheral Versus Lymph Node Chronic Lymphocytic Leukemia Cells Is Correlated with Survival Capacity.
Authors: Delfine Y.H. Hallaert, Laura A. Smit, Rene Spijker, Bart de Goeij, Annelieke Jaspers, Arnon P. Kater, Marinus H. van Oers, Carel J.M. van Noesel, Eric Eldering
Journal: Blood (2006)
Risk of treatment failure after first-line sunitinib therapy in patients with metastatic renal cell carcinoma.
Authors: Chi-Chang Chen, Gregory P. Hess, Zhimei Liu, Dean H. Gesme, Sanjiv S. Agarwala, Jerrold W. Hill, Min Amy Guo
Journal: Journal of Clinical Oncology (2012)

438 Background: Treatment options for metastatic renal cell carcinoma (mRCC) are rapidly evolving. Current treatment options include surgery, immunotherapy, and several targeted therapies including kinase inhibitors, mTOR inhibitors and anti-VEGF agents. The aim of this study was to inform choices and outcomes on the sequential use of targeted therapies for mRCC through the evaluation of the comparative effectiveness of common second-line targeted therapies following 1 st line sunitinib treatment. Methods: A retrospective observational study using claims data was conducted. Final study subjects were mRCC patients who received everolimus, sorafenib or temsirolimus from 4/1/2008 to 2/29/2011 following 1 st line sunitinib treatment. Patients were followed from the start of second-line treatment until treatment failure or last observation in the database. Treatment failure was defined as advancement to a third-line of mRCC therapy, or mortality. Results were analyzed using Cox proportional hazards model controlling for baseline clinical and demographic factors. Results: The study sample consisted of 257 mRCC patients who received everolimus (n=117), temsirolimus (n=75) and sorafenib (n=65) following 1 st line sunitinib treatment. Patients had a mean age of 63 years, and 72% were male. The mean observation period from the start of second-line treatment was ∼6.4 months. Treatment failure was observed in 38.5% (20.2% advanced from 2 nd to 3 rd line and 18.3% died) of the study sample and 61.5% of patients were censored at last observation without any treatment failure event. Results from the Cox proportional hazards model indicated that, compared to everolimus, both sorafenib and temsirolimus patients experienced a statistically significant higher adjusted risk of treatment failure (sorafenib: HR=1.77, p=0.043; temsirolimus: HR=2.05, p=0.004). Conclusions: Following systemic treatment for mRCC with first-line sunitinib, patients on second-line targeted therapies were observed with differential risks of treatment failure, as defined by line advancement or death. The risk of treatment failure was significantly higher with sorafenib and temsirolimus as compared to everolimus.
Should log odds of positive lymph node be incorporated into AJCC TNM breast cancer staging system?
Authors: J. Wang, S. J. Anderson, J. P. Costantino, E. P. Mamounas, J. M. Hassett, N. Wolmark
Journal: Journal of Clinical Oncology (2008)

11037 Background: The number of positive lymph nodes (NPLN) can be influenced by the extent of lymph node (LN) dissection, and the extent of pathologic evaluation. These factors could result in understaging patients. A recent study using SEER data showed that log odds of positive lymph nodes (LODDS) is a better prognostic factor than NPLN. This study reports the confirmatory result using patients included in prospective, randomized clinical trials by the NSABP. Methods: 9,862 patients who had follow-up information were identified from four node-positive NSABP trials The LODDS is defined as: log[(N1+0.5)/( N0+0.5)], where N1 is NPLN and N0 is the number of negative LN. Five subgroups of patients are identified using the cutoff points - 2.2,-1.1, 0, and 1.1 for LODDS. The prognostic effects of LODDS on overall survival (OS) were evaluated via Kaplan-Meier curves, log-rank tests and Cox models. Results: Results from multivariate Cox models indicate that LODDS analyzed as a continuous variable is an independent prognostic factor for OS even after adjusting for patients’ age, tumor size, grade, ER status and NPLN (HR=1.34 95%CI 1.31 - 1.38, p< 0.00001). Furthermore, the relationship between LODDS and OS is stronger than the relationship between NPLN and OS. The 10-year survival for stage IIIA patients in the five LODD categories is 68.7%, 68.0%, 60.4%, 51.0% and 45.9%, respectively (p<0.0001). Similar patterns are observed for patient with stage IIIC, IIA and IIB disease as reported in Table 1. Conclusions: LODDS is an independent prognostic factor of OS and is better than using NPLN. This study further confirms that the patients classified using the current AJCC stages IIA, IIB, IIIA, and IIIC have heterogeneous prognoses even after adjusting for nodal status. Using LODDS or another measure of nodal status as well as using non-anatomic factors such as ER and HER2 status should be considered in order to improve the current TNM staging system. 10-year survival (%) by AJCC Stage and LODDS For Patients in NSABP B-22, B-25, B-28 and B-31 AJCC Stage LODDS Category All patients in LODDS1 to 5 1 2 3 4 5 IIA (n=2912) 86.1 82.3 72.2 71.3 87.5** 81.9 IIB (n=2528) 73.9 71.6 69.8 58.8 57.1** 71.8 IIIA (n=3283) 68.7 68.0 60.4 51.0 45.9 59.9 IIIC (n=1010) N/A* 100** 54.2 43.9 34.3 40.9 * No patients were at risk in this category; ** ≤10 patients were at risk in this category No significant financial relationships to disclose.
Academic Detailing
Authors: Jerry Avorn
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML
Authors: Rebecca Warfvinge, Linda Geironson, Mikael N. E. Sommarin, Stefan Lang, Christine Karlsson, Teona Roschupkina, Leif Stenke, Jesper Stentoft, Ulla Olsson-Strömberg, Henrik Hjorth-Hansen, Satu Mustjoki, Shamit Soneji, Johan Richter, Göran Karlsson
Journal: Blood (2017)
Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN
Authors: Debra K Czerwinski, Steven R Long, Michael Khodadoust, Matthew J. Frank, Michael P. Chu, Ami Okada, Kathleen A McDonald, Holbrook E Kohrt, Nancy L Bartlett, Patrick M. Reagan, Jonathan W. Friedberg, Leo I. Gordon, Robert Coffman, Robert Janssen, Ronald Levy
Journal: Blood (2015)
A pediatric phase I trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A Children’s Oncology Group Phase I Consortium Study.
Authors: T. R. Hummel, L. M. Wagner, C. H. Ahern, R. M. McGovern, M. M. Ames, R. J. Gilbertson, T. M. Horton, A. M. Ingle, B. Weigel, S. Blaney
Journal: Journal of Clinical Oncology (2011)

9579 Background: The looser chromatin structure seen following treatment with histone deacetylase (HDAC) inhibitors is hypothesized to render cells more sensitive to drugs targeting DNA. A phase I trial of vorinostat (VOR), an HDAC inhibitor, combined with temozolomide (TEM) was conducted to investigate the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of this combination. VOR pharmacokinetics (PK), serum MGMT promoter status, and histone acetylation in peripheral blood mononuclear cells were also assessed. Methods: VOR followed by TEM were orally administered, once daily, for 5 consecutive days every 28 days at 3 dose levels using the rolling 6 design. The respective dose levels for VOR and TEM were: (1) 230 mg/m2/day; 150 mg/m2/day, (2) 300 mg/m2/day; 150 mg/m2/day and (3) 300 mg/m2/day; 200 mg/m2/day. Studies of histone accumulation in peripheral blood mononuclear cells were performed on day 1 at 0, 6, and 24 h after vorinostat dosing. Vorinistat pharmacokinetics (PK) and serum MGMT promoter status were also assessed. Results: Nineteen eligible patients, 12 males, median age 8 yrs (range, 2-20 ) with high grade glioma [n=7], ependymomas [n=4], medulloblastoma [n=2], PNET [n=2], ATRT [n=2], carcinoma [n=1], and ganglioglioma [n=1] were enrolled. Seventeen patients were fully evaluable for toxicity. There were no DLTs observed at dose level 1 (n=6) or 2 (n=6). DLT (myelosuppression) occurred in 2 patients at dose level 3: thrombocytopenia [n=2] and neutropenia [n=1]. Non-dose–limiting grade 3 or 4 toxicities related to protocol therapy were hematologic and included neutropenia [n=8], lymphopenia [n=7], thrombocytopenia [n=6], anemia [n=1] and leucopenia [n=6]. No grade 5 drug-related serious adverse events were observed. Results of PK and correlative biology studies will be presented. Conclusions: Five-day courses of VOR 300 mg/m2/day in combination with TEM 150 mg/m2/day are well tolerated in children with recurrent CNS malignancies.
TMOD-05MODELING ACVR1 AND HIST1H3B MUTATIONS IN DIFFUSE INTRINSIC PONTINE GLIOMA<i>IN VIVO</i>USING THE SLEEPING BEAUTY SYSTEM
Authors: Flor Mendez, Felipe Nunez, Carl Koschmann, Alexandra Calinescu, Neha Kamran, Marta Dzaman, Pedro Lowenstein, Maria Castro
Journal: Neuro-Oncology (2015)

Diffuse intrinsic pontine glioma (DIPG) is a brainstem tumor that occurs in the pons in children; median age 6-7 years. The most frequent DIPG mutations affect the N-terminal tail of histone H3.3 and histone H3.1 and result in the change of a lysine to methionine at residue 27. In addition, six recurrent somatic activating mutations in ACVR1, which encodes for the bone morphogenetic protein (BMP) receptor kinase, have also been identified in DIPG tumors. We aim to use the sleeping beauty transposase system to generate spontaneous in vivo tumor models that will allow us to test the contributions of these genes to the pathogenesis of DIPG tumors. We have cloned ACVR1 G328V, and HIST1H3B K27M sequences into a plasmid that contains flanking inverted repeats (IR) which contain binding sequences for the sleeping beauty transposase, which will excise DNA between the IR sites and insert it into the host genome. Plasmids encoding a short hair pin for p53, oncogenic NRAS, the sleeping beauty transposase/luciferase were injected with group 1: ACVR1 G328V; group 2: HIST1H3B K27M; or group 3: ACVR1 G328V and HIST1H3B K27M into the subventricular zone of neonatal mice. Tumor development in mice is monitored by measuring luciferase activity in vivo; animals that have reached moribund stage are perfused and processed for histology. Our long-term goal is to understand the interplay between the ACVR1 activating mutation and the histone H3K27M mutation. The ACVR1 mutations result in constitutive BMP pathway activation and the H3K27M mutation has been shown to globally alter H3K27 methylation. Through this study we hope to elucidate how ACVR1 mutations and H3K27 mutations contribute to tumor progression in order to uncover novel therapeutic targets for DIPG which would improve prognosis for DIPG patients.
Annular Plaques With Skin Atrophy in a Young Patient
Authors: Eray Yihui Zhou, Yi Zhao, Zhimiao Lin
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Genetic Modifiers Influencing the Development of Albuminuria in Children with Sickle Cell Anemia
Authors: Beverly A Schaefer, Jonathan M Flanagan, Banu Aygun, Ofelia A. Alvarez, Stephen C Nelson, Kerri A Nottage, Carla W Roberts, Thad A. Howard, Barry R Davis, Russell E. Ware
Journal: Blood (2015)
Fostamatinib Inhibits BCR Signaling, and Reduces Tumor Cell Activation and Proliferation in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia.
Authors: Sarah E. M. Herman, Paul M. Barr, Erin M. McAuley, Delong Liu, Jonathan W. Friedberg, Adrian Wiestner
Journal: Blood (2012)
A Randomized Prospective Multicenter Phase III Trial Comparing Standard GvHD Prophylaxis with Cyclosporine and Methotrexate with Additional Pretransplant ATG Fresenius (ATG-F) in Allogeneic Stem Cell Transplantation from Matched Unrelated Donors
Authors: Jürgen Finke, Wolfgang Andreas Bethge, Claudia Schmoor, Hellmut Ottinger, Matthias Stelljes, Axel Zander, Liisa Volin, Dominik Heim, Rainer Schwerdtfeger, Karin Kolbe, Jiri Mayer, Johan Maertens, Werner Linkesch, Ernst Holler, Vladimir Koza, Martin Bornhaeuser, Hermann Einsele, Hans-Jochem Kolb, Hartmut Bertz, Matthias Egger, Olga Grichina, Gerard Socie
Journal: Blood (2008)
Delayed premature menopause following chemotherapy for early stage breast cancer: Long-term results from IBCSG Trial V
Authors: A. H. Partridge, S. Gelber, R. Gelber, A. Goldhirsch, E. P. Winer
Journal: Journal of Clinical Oncology (2005)

687 Background: The likelihood of delayed, but nevertheless premature, menopause following chemotherapy has not been thoroughly explored in women who remain premenopausal immediately following adjuvant chemotherapy for breast cancer. Methods: We evaluated the age of menopause in women with early stage breast cancer who remained premenopausal using data from the International Breast Cancer Study Group (IBCSG) Trial V. From 1981–1985, 1407 premenopausal women were randomized by nodal status: 692 with node-neg disease received either no systemic therapy (NC) or CMFx1 preoperatively (Cp); 715 with node-pos disease received either Cp, CMFx6 postoperatively (CT), or CT+Cp. Median follow-up is over 19 years. Results: Women who reported no menses during 12–24 months after enrollment (N=660), history of hysterectomy (N=15) or oophorectomy (N=7), or missing 12–24 month menses data (N= 53) were excluded, leaving 672 women in the following age at diagnosis groups: < 35 years (N=96), 35–39 years (N=154), and 40–44 years (N= 422). 540 women had received NC or Cp (mean age = 42 years); 132 had received CT or Cp+CT (mean age = 38 years). Using a Cox proportional hazards model, censoring at recurrence, new primary or death, factors associated with age at onset of menopause were: age at dx (HR= 0.88 per year, p<0.0001), randomization to 6 or 7 cycles of CMF (HR = 2.11, p<0.0001), and temporary amenorrhea at any point during 0–24 months post randomization (HR= 34.36, p<0.0001). Among these women premenopausal 2 years following randomization, alive and disease free at 5 years (N=480) and 10 years (N= 316), women who were in menopause by 5 and 10 years by age at diagnosis and treatment using logistic regression is presented below: Conclusions: Women who remain premenopausal after 6 or 7 cycles of CMF have a higher likelihood of going through menopause at an earlier age than women who have received 0 or 1 cycle, particularly for women diagnosed after age 35. Temporary cessation of menses appears to be a marker for earlier onset of menopause. These findings may assist young women with breast cancer when making treatment decisions. No significant financial relationships to disclose.
STUDIES ON ENTRY AND EGRESS OF POLIOMYELITIC INFECTION
Authors: Harold K. Faber, Rosalie J. Silverberg, Luther Dong
Journal: The Journal of Experimental Medicine (1953)

Poliomyelitis virus, when ingested by cynomolgus monkeys in their regular food, infected peripheral ganglia (nodose) as early as the 3rd day, as shown by recovery of the virus. Conditions on the 2nd and 4th days were not investigated, but on the 5th and 6th days, virus was recovered from the Gasserian and nodose ganglia, and from the superior cervical sympathetic and celiac ganglia. The findings indicate that the method of oropharyngeal swabbing used in a study already reported and the method of simple feeding used in the present study produce comparable results. Viremia, noted in the present study, was contemporaneous with virus recoveries from the ganglia. Reasons are presented why the peripheral ganglia are the most probable source of viremia since these are the only known site of early lesions (which are typical and appear as early as the 2nd day after oral infection) and no lesions are known to occur in extraneural tissues. Invasion of the CNS occurred in 3 animals out of 11; one on the 5th and 2 on the 6th day. Whether this was due to viremia or to centripetal extension along axonal channels is not clear.
Mechanisms of Suppression Used by Regulatory T Cells in Patients Newly Diagnosed with Acute Myeloid Leukemia
Authors: Miroslaw J Szczepanski, Marta Szajnik, Malgorzata Czystowska, Magis Mandapathil, Ann Welsh, Kenneth Foon, Theresa L Whiteside, Michael Boyiadzis
Journal: Blood (2008)
The Role of An Early Interim 18 F-FDG PET/CT for Prediction of Outcomes of Patients with Peripheral T Cell Lymphoma
Authors: Yoon Hee Choi, Byung Woog Kang, Hyun Soo Hong, Chul Kim, Geundoo Jang, Sung Sook Lee, Jin Sook Ryu, Jooryung Huh, Dae Ho Lee, Sang We Kim, Jung Shin Lee, Cheolwon Suh
Journal: Blood (2008)
Translating Cancer Surveillance Data Into Effective Public Health Interventions
Authors: Stephanie B. Wheeler, Ethan Basch
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Genomic and Targeted Mutational Analysis of T/NK-Cell Post-Transplant Lymphoproliferative Disorders Provides Insight into Disease Biology
Authors: Elizabeth Michelle Margolskee, Vaidehi Jobanputra, Preti Jain, Jinli Chen, Odelia Nahum, Brynn Levy, Karthik A Ganapathi, Vundavalli Murty, Thomas Tousseyn, Bachir Alobeid, Mahesh Manuskhani, Govind Bhagat
Journal: Blood (2015)